MX2012003924A - Antagonistas peptidicos sinteticos de miostatina. - Google Patents

Antagonistas peptidicos sinteticos de miostatina.

Info

Publication number
MX2012003924A
MX2012003924A MX2012003924A MX2012003924A MX2012003924A MX 2012003924 A MX2012003924 A MX 2012003924A MX 2012003924 A MX2012003924 A MX 2012003924A MX 2012003924 A MX2012003924 A MX 2012003924A MX 2012003924 A MX2012003924 A MX 2012003924A
Authority
MX
Mexico
Prior art keywords
peptide antagonists
synthetic
myostatin peptide
myostatin
synthetic myostatin
Prior art date
Application number
MX2012003924A
Other languages
English (en)
Inventor
Robert Syndecombe Bower
Monica Senna Salerno De Moura
Gina Diane Nicholas
Mark Francis Thomas
Carole Judith Berry
Original Assignee
Covita Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covita Ltd filed Critical Covita Ltd
Publication of MX2012003924A publication Critical patent/MX2012003924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)

Abstract

La presente invención se refiere a los nuevos antagonistas sintéticos de miostatina, que comprenden un péptido de miostatina maduro, sintético, en donde el péptido comprende al menos dos residuos de cisteína en las posiciones 281 y 282, que son forzados a enlazase y a formar un enlace disulfuro o una variante o fragmento funcional del mismo, y son útiles en el tratamiento de trastornos relacionados a la miostatina.
MX2012003924A 2009-10-01 2010-09-29 Antagonistas peptidicos sinteticos de miostatina. MX2012003924A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24782109P 2009-10-01 2009-10-01
PCT/NZ2010/000191 WO2011040823A1 (en) 2009-10-01 2010-09-29 Synthetic myostatin peptide antagonists

Publications (1)

Publication Number Publication Date
MX2012003924A true MX2012003924A (es) 2012-08-03

Family

ID=43826485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003924A MX2012003924A (es) 2009-10-01 2010-09-29 Antagonistas peptidicos sinteticos de miostatina.

Country Status (11)

Country Link
US (1) US20130065820A1 (es)
EP (1) EP2483300A4 (es)
JP (1) JP2013506660A (es)
KR (1) KR20120082909A (es)
CN (1) CN102741276A (es)
AU (1) AU2010301196A1 (es)
BR (1) BR112012007563A2 (es)
CA (1) CA2776529A1 (es)
MX (1) MX2012003924A (es)
NZ (1) NZ599604A (es)
WO (1) WO2011040823A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087946A1 (en) * 2010-01-15 2011-07-21 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
SG11201507413XA (en) * 2013-03-15 2015-10-29 Amgen Inc Myostatin antagonism in human subjects
AU2015342936B2 (en) 2014-11-06 2020-10-08 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
JP7032808B2 (ja) * 2016-08-10 2022-03-09 学校法人東京薬科大学 ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
RS64159B1 (sr) * 2017-01-06 2023-05-31 Scholar Rock Inc Tretiranje metaboličkih bolesti inhibiranjem aktivacije miostatina
EP3761783A4 (en) * 2018-02-26 2021-12-15 The Trustees of Columbia University in the City of New York ZINC ASSOCIATED TREATMENT AND DIAGNOSIS OF CACHEXIA
WO2019179361A1 (zh) * 2018-03-21 2019-09-26 傅惠芳 改善括约肌闭锁不全的组合物及其医药组成物与用途
EP3769779B1 (en) * 2018-03-21 2023-12-27 Soulyoung Biotech Co., Ltd Composition for promoting local muscle growth or slowing down or preventing local muscle atrophy and use thereof
TWI649332B (zh) * 2018-03-21 2019-02-01 英屬安圭拉商維多利亞生物醫學控股股份有限公司 Composition for promoting local muscle growth, slowing or preventing local muscle atrophy and use thereof
WO2021060880A1 (ko) * 2019-09-24 2021-04-01 마이오텍사이언스 주식회사 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
JP2003517580A (ja) * 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
US8309068B2 (en) * 2006-08-03 2012-11-13 Myostin Therapeutics Pty Ltd. Isolated polypeptides and methods of improving muscle strength

Also Published As

Publication number Publication date
JP2013506660A (ja) 2013-02-28
EP2483300A4 (en) 2013-02-27
WO2011040823A1 (en) 2011-04-07
BR112012007563A2 (pt) 2019-09-24
CA2776529A1 (en) 2011-04-07
CN102741276A (zh) 2012-10-17
KR20120082909A (ko) 2012-07-24
AU2010301196A1 (en) 2012-05-17
EP2483300A1 (en) 2012-08-08
US20130065820A1 (en) 2013-03-14
NZ599604A (en) 2014-07-25

Similar Documents

Publication Publication Date Title
MX2012003924A (es) Antagonistas peptidicos sinteticos de miostatina.
ZA201001054B (en) Peptide with reduced dimer formation
IN2014DN09805A (es)
TN2014000134A1 (en) Therapeutic peptides
MY158438A (en) Antibodies against human angiopoietin 2
EP3486319A3 (en) Compositions and methods comprising serine protease variants
IN2014DN09804A (es)
WO2009087082A3 (de) Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
FR2959658B1 (fr) Bande de restauration de l'attache a un os d'un tissu mou tel qu'un tendon ou un ligament
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
MX2010004571A (es) Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos.
HK1141474A1 (en) Cyclic peptide cxcr4 antagonists
MY181181A (en) Fgf21 derivatives and uses thereof
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
GB0710529D0 (en) Vaccine
DE602006014250D1 (de) Flammhemmende kautschukzusammensetzung und kautschukprodukt daraus sowie beschichtungsmaterial für einen elektrischen draht
CR11741A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
GB2492738A (en) Conjugated blood coagulation factor VIIA
NZ603939A (en) Conjugated blood coagulation factor viii
BRPI0906027A2 (pt) "composições de poliamida, processos de fabricação de uma composição de poliamida e artigos"
WO2006110724A3 (en) Method of treating schizophrenia prodrome
TN2009000447A1 (en) An extented-release composition comprising a somatostatin derivative in microparticles
EP2301951A4 (en) PEPTIDE DERIVATIVE AND COMPOSITION FOR PROMOTING TEAR SECRETION COMPRISING SAME
UA104714C2 (ru) Выделенный полинуклеотид brachyspira hyodysenteriae, кодирующий полипептид, и его применение
WO2007103584A3 (en) Polyamides for treating human papilloma virus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal